



Industry Insight

# Cygnus

**Business Consulting & Research**

*Knowledge Partner For Profitable Growth*

**Cygnus Business Consulting & Research**

4<sup>th</sup> & 5<sup>th</sup> Floors, Astral Heights, Road No. 1, Banjara Hills, Hyderabad-500034, India

Tel: +91-40-23430203-05, Fax: +91-40-23430201, E-mail: [info@cygnusindia.com](mailto:info@cygnusindia.com)

Website: [www.cygnusindia.com](http://www.cygnusindia.com)

## CONTENTS

1. Executive Summary
2. Highlights
3. Industry Overview
  - 3.1 Introduction
  - 3.2 Industry growth
    - 3.2.1 Industry concentric
    - 3.2.2 Industry analysis
    - 3.2.3 R&D expenditure
    - 3.2.4 Strength of the players
    - 3.2.5 Financial flow
    - 3.2.6 NASDAQ biotech index
  - 3.3 The segments
    - 3.3.1 Biopharmaceuticals
    - 3.3.2 Agri-biotechnology
    - 3.3.3 Bioindustry
  - 3.4 Conclusion
  - 3.5 References
4. Growth Drivers
  - 4.1 Introduction
  - 4.2 The Push behind the Move: Key Growth Drivers
    - 4.2.1 Therapy areas and technology-The expanding horizon
    - 4.2.2 Favorable regulations
    - 4.2.3 Expanding Clientele and market hold
    - 4.2.4 Aging population and life style
    - 4.2.5 Financing abilities
    - 4.2.6 Enhanced Entrepreneurial Culture
    - 4.2.7 Positive growth of related industries
    - 4.2.8 Growth of Contract Research Organizations
  - 4.3 Growth Drivers: Past and the present
  - 4.4 Conclusion
    - 4.4.1 Integrated Biotechnology
    - 4.4.2 Developing and the co-development of companies
    - 4.4.3 Increased drug targets through genomics
  - 4.5 References
5. Issues and Challenges
  - 5.1 Introduction
  - 5.2 Where does the shoe pinches? Major Issues and Challenges
    - 5.2.1 Answer to the ever decreasing fossil fuel
    - 5.2.2 Food safety and security
    - 5.2.3 Human health and medicine

- 5.2.4 Sustainability of environment
- 5.2.5 Bioterrorism
- 5.2.6 Human Genome Project
- 5.2.7 Cloning and stem cell research - an ethical issue
- 5.2.8 Genetically Modified Foods - How safe are they?
- 5.2.9 Biosafety and the concern of environmentalists
- 5.2.10 Animal rights issue, violent at times
- 5.2.11 Biopiracy
- 5.2.12 Data Exclusivity (DE)
- 5.2.13 Royalty Stacking

### 5.3 Tackling the issues and challenges

- 5.3.1 Equal access of the technology
- 5.3.2 Establishment of biotechnology associations
- 5.3.3 Financial Resources
- 5.3.4 Concerted working of the various research organizations
- 5.3.5 Balanced and accurate dissemination of information
- 5.3.6 Solutions to royalty stacking issue

### 5.4 Conclusion

### 5.5 References

## 6. Technology

### 6.1 Introduction

### 6.2 Important technologies

- 6.2.1 Polymerase chain reaction
- 6.2.2 Restriction enzymes and ligases
- 6.2.3 Radioactive tracer
- 6.2.4 Bioprocess technology
- 6.2.5 Biotechnology Diagnostics
- 6.2.6 Monoclonal antibody
- 6.2.7 Cloning
- 6.2.8 Genetic therapy
- 6.2.9 Biosensors
- 6.2.10 Biocomputer
- 6.2.11 Bionanotechnology
- 6.2.12 Microarray
- 6.2.13 Transgenic Plants
- 6.2.14 Nutraceuticals
- 6.2.15 Bioinformatics
- 6.2.16 Bioremediation
- 6.2.17 Antisense technology
- 6.2.18 Proteomics
- 6.2.19 Stem cell technology

### 6.3 Technological application for integrating value chain

### 6.4 Changes in technology and its application during 2005

### 6.5 Conclusion

- 6.5.1 Stem cells
- 6.5.2 Gene therapy

- 6.5.3 Agriculture
- 6.5.4 Cloning
- 6.6 References
- 7. Major Markets
  - 7.1 Introduction
  - 7.2 North America
    - 7.2.1 The economy
    - 7.2.2 Biotechnology Industry
    - 7.2.3 Major Biotechnology clusters
    - 7.2.4 Areas of focus
  - 7.3 Europe
    - 7.3.1 The economy
    - 7.3.2 Biotechnology Industry
    - 7.3.3 Major biotechnology clusters in Europe
    - 7.3.4 Areas of focus
  - 7.4 Asia Pacific
    - 7.4.1 The economy
    - 7.4.2 Biotechnology industry
    - 7.4.3 Emerging countries of Asia Pacific
    - 7.4.4 Areas of focus
  - 7.5 Conclusion
  - 7.6 References
- 8. Major Players
  - 8.1 Introduction
  - 8.2 Amgen, Inc
    - 8.2.1 Business Profile
    - 8.2.2 Financial and operational performance
    - 8.2.3 Business Strategy: Amgen
    - 8.2.4 Future Outlook
  - 8.3 Genentech
    - 8.3.1 Business Profile
    - 8.3.2 Financial and operational performance
    - 8.3.3 Business Strategy: Genentech
    - 8.3.4 Future Outlook
  - 8.4 Genzyme
    - 8.4.1 Business Profile
    - 8.4.2 Financial and operational performance
    - 8.4.3 Business Strategy: Genzyme
    - 8.4.4 Future Outlook
  - 8.5 Serono SA
    - 8.5.1 Business Profile
    - 8.5.2 Financial and operational performance
    - 8.5.3 Business Strategy: Serono SA
    - 8.5.4 Future Outlook

## 8.6 Biogen Idec

- 8.6.1 Business Profile
- 8.6.2 Financial and operational performance
- 8.6.3 Business Strategy: Biogen Idec
- 8.6.4 Future Outlook

## 8.7 Gilead

- 8.7.1 Business Profile
- 8.7.2 Financial and operational performance
- 8.7.3 Business Strategy: Gilead
- 8.7.4 Future Outlook

## 8.8 Chiron Corporation

- 8.8.1 Business Profile
- 8.8.2 Financial and operational performance
- 8.8.3 Business Strategy: Chiron Corporation
- 8.8.4 Future Outlook

## 8.9 MedImmune

- 8.9.1 Business Profile
- 8.9.2 Financial and operational performance
- 8.9.3 Business Strategy: MedImmune
- 8.9.4 Future Outlook

## 8.10 Invitrogen

- 8.10.1 Business Profile
- 8.10.2 Financial and operational performance
- 8.10.3 Business Strategy: Invitrogen
- 8.10.4 Future Outlook

## 8.11 Millennium Pharmaceuticals Inc

- 8.11.1 Business Profile
- 8.11.2 Financial and operational performance
- 8.11.3 Business Strategy: Millennium
- 8.11.4 Future Outlook

## 8.12 Monsanto

- 8.12.1 Business Profile
- 8.12.2 Financial and operational performance
- 8.12.3 Business Strategy: Monsanto
- 8.12.4 Future Outlook

## 8.13 Syngenta

- 8.13.1 Business Profile
- 8.13.2 Financial and operational performance
- 8.13.3 Future Outlook

## 8.14 References

## 9. Regulations

### 9.1 Introduction

### 9.2 Regulatory bodies worldwide

- 9.2.1 US
- 9.2.2 EU

- 9.2.3 Japan
- 9.2.4 Australia
- 9.2.5 India
- 9.2.6 International organizations involved in regulations
- 9.3 Laws governing the biotechnology industry
  - 9.3.1 The US Laws and Regulations
  - 9.3.2 EU
  - 9.3.3 Japan
  - 9.3.4 India
- 9.4 Regulatory Changes
  - 9.4.1 UK
  - 9.4.2 India
  - 9.4.3 Croatia
- 9.5 Conclusion
- 9.6 References
- 10. Mergers and Acquisitions
  - 10.1 Introduction
  - 10.2 Drivers for M&A
    - 10.2.1 Product and market extension
    - 10.2.2 Acquire new technology
    - 10.2.3 Operate in new geographies
    - 10.2.4 Wide and cost effective research and development (R&D)
    - 10.2.5 Gaining critical mass
    - 10.2.6 Finance from investors
    - 10.2.7 Implementation of core capability
  - 10.3 Trends of M&A: The way things are happening
    - 10.3.1 The urge to merge: Heating up around the globe
    - 10.3.2 Major M&A in the last 3 years, 2003-2005
    - 10.3.3 M&A in 2005: Few giants on a buying spree
  - 10.4 M&A of the year 2005
    - 10.4.1 Novartis AG: Chiron
  - 10.5 Conclusions
  - 10.6 References
- 11. Critical Success Factors
  - 11.1 Introduction
  - 11.2 Stimulant of Growth: The Critical Success Factors
    - 11.2.1 Government initiatives
    - 11.2.2 Research and Development (R&D)
    - 11.2.3 Entrepreneurial Environment
    - 11.2.4 Mix of companies in value chain; Proportionate distribution
    - 11.2.5 Spin-offs and start-up firms-The incubators
    - 11.2.6 Effective commercialization
    - 11.2.7 Venture Capital and IPO: The source of sustenance
    - 11.2.8 Critical Alliances: Partnering for Progressing

- 11.3 Critical Success Factors-Past and the present
- 11.4 Critical Success Factors-Present and the future
- 11.5 References
- 12. Future Outlook
  - 12.1 References

## **LIST OF FIGURES (50)**

- Figure 3.1: Biotech Industry Revenues 2002-2005
- Figure 3.2: Global revenue breakup, 2005
- Figure 3.3: Global revenue breakup, 2001-2005
- Figure 3.4: Global Industry net loss, 2001-2005
- Figure 3.5: R&D expenditure in the industry, 2001-2005
- Figure 3.6: Companies in biotech industry, 2001-2005
- Figure 3.7: Biotech financing, 1998-2005
- Figure 3.8: Major indices (base 100 on January 01, 1998)
- Figure 3.9: Global Coverage of GM crops, 1997-2005
- Figure 4.1: Financing, the US Biotech companies, 2003-2005
- Figure 4.2: Market Capitalization, biotechnology companies, 2000-2005
- Figure 6.1: Value chain in Biotechnology Industry
- Figure 7.1: Major Region of Biotech Industry, 2001-2005
- Figure 7.2: North American GDP, 2001-2005
- Figure 7.3: North American Biotech Revenue, 2001-2005
- Figure 7.4: North American R&D Expenditure, 2001-2005
- Figure 7.5: Biotech Companies in North America, 2001-2005
- Figure 7.6: European GDP, 2001-2005
- Figure 7.7: European Biotech Revenue, 2001-2005
- Figure 7.8: Biotech Companies in Europe, 2001-2005
- Figure 7.9: R&D Investment in Europe, 2001-2005
- Figure 7.10: Asian GDP, 2001-2005
- Figure 7.11: Biotech Revenue in Asia and Asia Pacific, 2001-2005
- Figure 7.12: Biotech companies in Asia Pacific, 2001-2005
- Figure 7.13: R&D expenditure in Asia, 2001-2005
- Figure 8.1: Amgen Inc price movement in 2005 (NASDAQ)
- Figure 8.2: Genentech price movement in 2005 (NASDAQ)
- Figure 8.3: Genzyme price movement in 2005 (NASDAQ)

- Figure 8.4: Serono SA price movement in 2005 (NASDAQ)
- Figure 8.5: Biogen Idec price movement in 2005 (NASDAQ)
- Figure 8.6: Gilead price movement in 2005 (NASDAQ)
- Figure 8.7: Chiron price movement in 2005 (NASDAQ)
- Figure 8.8: MedImmune price movement in 2005 (NASDAQ)
- Figure 8.9: Invitrogen price movement in 2005 (NASDAQ)
- Figure 8.10: Millennium price movement in 2005 (NASDAQ)
- Figure 8.11: Monsanto price movement in 2005 (NASDAQ)
- Figure 8.12: Syngenta price movement in 2005 (NASDAQ)
- Figure 9.1: Regulatory framework in the US
- Figure 9.2: Regulatory framework in India
- Figure 9.3: National Biotechnology Development Strategy (Draft), 2005
- Figure 10.1: Net value (Top 10 deals) and highest deal
- Figure 10.2: Total value of M&A deals (USDm)
- Figure 10.3: Share of Novartis, Pfizer in the top 10 deals, 2005
- Figure 11.1: Government initiatives in biotechnology industry, Singapore
- Figure 11.2: Government initiatives in biotechnology industry, China
- Figure 11.3: Time spent in different R&D activities by a biotechnology company
- Figure 11.4: The US biotech financing, 2004
- Figure 11.5: Nature of strategic alliances, biotechnology companies
- Figure 12.1: Global Biotechnology Market, 2003-06 and 2010
- Figure 12.2: Market share of different regions

## **LIST OF TABLES (44)**

- Table 3.1: Time lag of companies from inception to first product commercialization
- Table 3.2: Biotech new drugs approved in 2004
- Table 3.3: Drugs approved for new indications
- Table 3.4: Biotech drugs in pipeline according to therapeutic segments
- Table 3.5: Patent expiration of major biotech drugs
- Table 3.6: Selected diagnostic products approved in 2005
- Table 5.1: Issues of bio piracy with some patents
- Table 6.1: New Technologies, Companies and its Application During 2005
- Table 7.1: Major companies in North America
- Table 7.2: North American biotechnology clusters
- Table 7.3: Major European companies
- Table 7.4: The UK biotechnology clusters

Table 7.5: Major biotechnology companies

Table 8.1: Top 10 biotechnology companies, 2005

Table 8.2: Financials of Amgen (2003-2005)

Table 8.3: Top selling drugs-Amgen(USDm), 2004-2005

Table 8.4: Financials of Genentech (2003-2005)

Table 8.5: Top selling drugs-Genentech(USDm), 2004-2005

Table 8.6: Products of Genentech in various stages up to February 2006

Table 8.7: Financials of Genzyme (2003-2005)

Table 8.8: Top selling drugs-Genzyme(USDm), 2004-2005

Table 8.9: Financials of Serono SA (2003-2005)

Table 8.10: Top selling drugs-Serono(USDm), 2004-2005

Table 8.11: Financials of Biogen Idec Inc (2003-2005)

Table 8.12: Top selling drugs- Biogen Idec Inc(USDm), 2004-2005

Table 8.13 Product Pipeline, Biogen Idec, as on March 2006

Table 8.14: Financials of Gilead (2003-2005)

Table 8.15: Top selling drugs- Gilead(USDm), 2004-2005

Table 8.16: Financials (USDm) of Chiron, 2003-2005

Table 8.17: Top selling drugs- Chiron(USDm), 2004-2005

Table 8.18: Financials of MedImmune, 2003-2005

Table 8.19: Top selling drugs- MedImmune(USDm), 2004-2005

Table 8.20: Financials of Invitrogen, 2003-2005

Table 8.21: Revenue earnings, 2004-2005

Table 8.22: Financials of Millennium, 2003-2005

Table 8.23: Sales of Velcade in US, 2004-2005

Table 8.24: Products in different stages

Table 8.25: Financials of Monsanto, 2003-2005

Table 8.26: Biotechnology seeds of Monsanto

Table 8.27: Product Pipeline of Monsanto (As on March 2006)

Table 8.28: Financial results, 2003-2005

Table 8.29: Product sales in seeds segment (in USDm), 2004-2005

Table 10.1: Top 10 deals in recent years, 2003-2005

Table 11.1: Noble Laureates as Founders of Biotechnology Farms

## Synopsis

**G**lobal Biotechnology report covers the industry size and its growth over the past few years. The segments of the industry along with growth drivers and issues and challenges of the industry are briefed. Core technologies in the industry and the top 10 global players of the industry are also discussed with their profiles. The regulatory environment and the associated bodies are mentioned for all the geographical regions and the critical success factors in the industry are highlighted. This report also has details on mergers and acquisitions in the industry and to end the report a future outlook for the industry has also been given.

Global biotech industry has continuously seen growth over the years. According to Cygnus Research, in the year 2005 this industry is estimated for worth USD63 billion revenues with a growth rate of around 16%; though this revenue is highly concentrated (mainly in North America). The agri biotechnology sector also continued its growth both in terms of innovation and market capitalization.

With all these favorable results in 2005 and the potential offered, the biotechnology industry is poised for a big leap in the near future. By 2010, the industry will have radical changes and market is expected to be more than USD128.5 billion. Bionanomedicine and nanotechnology finding enhanced application in disease treatment and drug delivery. Biotechnology would be a triumphant answer to the growing problem of environmental pollution and biodegradation. The pharma companies are increasingly realizing the potential of biotechnology to maintain their decreasing product pipeline and the threat posed by the fact that many blockbuster drugs are soon going to be off patented. So with all these happenings in the biotechnology industry this report promises to capture all the changes and growth.

This report is useful as an important business directional guide for professionals in biotechnology and Pharma industry as well as for those who are keen on having a firsthand overview of the industry.

Total PAGES: 179

TABLES: 44

FIGURES: 50